Merck CDR (CAD Hedged) (MRK : TSX)
Common Stock
$31.52
CAD
-0.78 (-2.41%)
Last updated: 2026-10-13
Dividend Declared
29 days ago$0.1887 CAD per share dividend. Ex-dividend date: September 15, 2026 • Payment date: October 15, 2026Upcoming
Follow MRK
MRK
Merck CDR (CAD Hedged)
WealthAwesomePerformance
1 Day
-2.41%
1 Week
+0.06%
1 Month
-1.68%
YTD
+31.22%
Key Statistics
Market Cap
$296.29B
52W High
$34.69
52W Low
$18.15
P/E Ratio
115.36
50 Day MA
$31.96
200 Day MA
$27.94
Beta
-
Dividend Yield
10.49%
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/13/2026 | $32.21 | $32.31 | $31.52 | $31.52 | $31.52 | 1,999 |
| 10/9/2026 | $31.77 | $32.55 | $31.77 | $32.30 | $32.30 | 18,900 |
| 10/8/2026 | $31.20 | $31.65 | $30.90 | $31.65 | $31.65 | 4,946 |
| 10/7/2026 | $31.68 | $31.70 | $31.60 | $31.60 | $31.60 | 1,987 |
| 10/6/2026 | $31.09 | $31.50 | $31.09 | $31.50 | $31.50 | 7,058 |
| 10/5/2026 | $31.68 | $31.68 | $30.99 | $31.02 | $31.02 | 9,331 |
| 10/2/2026 | $31.82 | $32.05 | $31.72 | $32.01 | $32.01 | 11,561 |
| 10/1/2026 | $32.20 | $32.24 | $31.88 | $31.92 | $31.92 | 22,010 |
| 9/30/2026 | $32.93 | $32.93 | $32.30 | $32.32 | $32.32 | 3,887 |
| 9/29/2026 | $33.13 | $33.19 | $32.50 | $33.19 | $33.19 | 23,126 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MRK's historical volatility
30-Day Vol
21.9%
Annualized
90-Day Vol
32.7%
Annualized
Trend (90d)
+41.9%
Annualized drift
90d Mean
C$36.60
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$33.13 | C$30.72 – C$35.73 |
| 60 trading days | C$34.82 | C$31.30 – C$38.74 |
| 90 trading days | C$36.60 | C$32.12 – C$41.71 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Merck CDR (CAD Hedged)
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- 3690.70%
- EPS (Diluted)
- 0.00
- Book Value
- -
Recent Dividends
$0.1887CAD
Ex: Sep 15, 2026
Pay: Oct 15
$0.1915CAD
Ex: Dec 15, 2025
$0.1848CAD
Ex: Sep 15, 2025
$0.1851CAD
Ex: Jun 16, 2025
$0.1837CAD
Ex: Mar 17, 2025
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About MRK
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
MRK.TO news timeline
2 articles covering MRK.TO, most recent first
Latest